IgG Autoantibodies from Bullous Pemphigoid (BP) Patients Bind Antigenic Sites on Both the Extracellular and the Intracellular Domains of the BP Antigen 180  by Perriard, Jacqueline et al.
IgG Autoantibodies from Bullous Pemphigoid (BP) Patients
Bind Antigenic Sites on Both the Extracellular and the
Intracellular Domains of the BP Antigen 180
Jacqueline Perriard, Fabienne Jaunin, Bertrand Favre, Lioba Bu¨dinger,* Michael Hertl,* Jean-Hilaire Saurat,
Luca Borradori
Department of Dermatology, DHURDV, University Hospital of Geneva, Geneva, Switzerland; *Department of Dermatology, Rheinisch-Westfa¨lische
Technische Hochschule, Aachen, Germany
Bullous pemphigoid (BP) and gestational pemphigoid
(PG) are subepidermal blistering disorders associated
with autoantibodies directed against two components
of hemidesmosomes: the BP antigen 180 (BP180) and
the BP antigen 230 (BP230). Autoantibodies against
the extracellular domain (ECD) of BP180 are thought
to play an initiatory role in subepidermal blister forma-
tion. To characterize the targeted antigenic sites on
BP180, we have assessed the reactivity of sera from
BP and PG patients against eukaryotic recombinant
proteins encompassing various portions of the ECD
and the intracellular domain (ICD) of BP180. Twenty-
two of 22 (100%) BP sera that immunoblotted BP180
in keratinocyte extracts, bound a mutant form con-
sisting of the entire ECD of BP180, whereas only three
of these 22 sera (14%) reacted against the ECD of
BP180 lacking the NC16A membrane proximal region.
Thirteen out of the 22 (59%) BP sera recognized the
ICD of BP180. Circulating IgG from a representative
BP patient that was affinity purified against the ECD
of BP180 did not bind the ICD when reblotted,
indicating that there was no antigenic cross-reactivity
between the ECD and the ICD of BP180. Reactivity
Bullous pemphigoid (BP) is an autoimmune subepider-mal blistering disease associated with in situ boundand circulating autoantibodies directed against theepidermal basement membrane zone (Jordon et al,1967; Stanley, 1983). The typical features of the
disease, which often affects the elderly, consist of large tense blisters
arising on normal or erythematous skin (Lever, 1953). Patients’
autoantibodies characteristically bind two components of hemides-
mosomes (HD): the bullous pemphigoid antigen 230 (BP230, also
termed bullous pemphigoid antigen 1) and the bullous pemphigoid
antigen 180 (BP180, also termed bullous pemphigoid antigen 2,
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against the ICD of BP180 was further ascertained by
immunofluorescence microscopy studies showing that
nine of the 22 (41%) BP sera stained COS-7 cells
expressing the ICD of BP180. Using deletion mutants
of the ICD of BP180, the majority of the sera was
found to recognize the central region of the ICD of
BP180. Specifically, an immunodominant region was
localized to an 87-amino acid segment located towards
the NH2-terminus of BP180. In contrast to BP sera,
five of six (83%) PG sera contained IgG that recognized
exclusively the NC16A region, whereas none bound
to the ICD of BP180. Together, the results indicate
that in BP, autoantibody reactivity to BP180 is not
exclusively restricted to the NC16A region, but that
additional antigenic determinants exist on the ICD of
BP180. The observed heterogeneous immune response
against BP180 might reflect intramolecular epitope
spreading. Because the ICD of BP180 harbors function-
ally important regions, it is possible that autoantibodies
against the ICD of BP180 have pathogenic significance
for the progression of the disease. Key words: auto-
immunity/hemidesmosome. J Invest Dermatol 112:141–147,
1999
or type XVII collagen) (Stanley et al, 1981, 1984; Labib et al,
1986). HD are multiprotein junctional complexes, that mediate
attachment of epithelial cells to the underlying basement membrane
in stratified and some complex epithelia, and provide a linkage
between elements of the cytoskeleton and the extracellular matrix
(Borradori and Sonnenberg, 1996; Green and Jones, 1996). BP230,
a cytoplasmic protein belonging to the plakin family (Green et al,
1992), is involved in the anchorage of keratin intermediate filaments
to the plasma membrane (Guo et al, 1995; Yang et al, 1996). In
BP230 null-mutant mice, HD lack the inner plaque and the
connection of intermediate filaments with HD is severely impaired
(Guo et al, 1995). In contrast, BP180 is a type II transmembrane
protein with a large extracellular collagenous domain (ECD), which
may act as a cell-surface receptor (Giudice et al, 1991, 1992;
Hopkinson et al, 1992; Li et al, 1992). The idea that BP180
promotes cell-substrate adhesion is supported by the observation
that mutations in the BP180 gene cause generalized atrophic
benign epidermolysis bullosa, an inherited skin blistering disorder
characterized by defective dermo–epidermal cohesion and impaired
formation of HD (Jonkman et al, 1995; McGrath et al, 1995).
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Recent transfection studies have identified domains within BP180
that are important for the localization of the protein into HD
(Hopkinson et al, 1995; Borradori et al, 1997). In addition, BP180
has been shown to interact with the α6β4 integrin (Hopkinson
et al, 1995; Borradori et al, 1997; Aho and Uitto, 1998; Schaapveld
et al, 1998), another transmembrane hemidesmosomal component,
as well as to affect the recruitment of BP230 into HD (Borradori
et al, 1998). These findings suggest that BP180 participates in the
stabilization of HD by interacting, directly or indirectly, with
various hemidesmosomal proteins.
The majority of BP patients possess circulating IgG that bind
BP230 and BP180 (Labib et al, 1986; Mueller et al, 1989; Giudice
et al, 1994; Matsumura et al, 1996; Zillikens et al, 1997a). Specifically,
recent studies have indicated that BP sera as well as gestational
pemphigoid (PG) sera, a disease closely related to BP (Morrison
et al, 1988), contain antibodies that predominantly react with an
immunodominant region on the ECD of BP180 close to the
transmembrane domain, the NC16A region (Giudice et al, 1993;
Matsumura et al, 1996; Zillikens et al, 1997b). Because rabbit
antibodies raised against the ECD of murine BP180, when injected
into neonatal mice, induce a blistering disorder mimicking BP (Liu
et al, 1993, 1995), it is thought that antibodies against the ECD of
BP180 are pathogenetically important. Nevertheless, their exact
contribution to the development of the disease in humans remains
unclear. Furthermore, it is unknown whether BP180 harbors
additional antigenic determinants. Recognition of distinct immuno-
dominant epitopes on BP180 may be relevant for the initiation
and perpetuation of the disease.
In this study, to further understand the pathophysiology of BP,
we have sought to identify epitopes other that those located in the
NC16A region by utilizing a series of recombinant forms of BP180
encompassing various portions of its ECD and its intracellular
domain (ICD). The reactivity of 33 BP sera was assessed by
immunoblotting analysis using extracts of transfected COS-7 cells
as well as by immunofluorescence (IF) microscopy. The results
indicate that BP180-specific IgG autoantibodies from BP patients
recognize multiple epitopes in both the ECD and the ICD of
BP180. It is likely that this heterogeneous response to BP180
reflects ‘‘intramolecular epitope spreading’’ (Vanderlugt and Miller,
1996; Chan et al, 1998) and may have pathogenic significance.
MATERIALS AND METHODS
Patients and controls Serum samples were obtained from adult patients
with BP (n 5 33), PG (n 5 6), epidermolysis bullosa acquisita (EBA; n 5
2), pemphigus vulgaris/pemphigus foliaceus (PV/PF; n 5 8), and healthy
volunteers (n 5 8). The clinical diagnosis of BP was confirmed by histology
(subepidermal blisters), direct IF microscopy (deposits of IgG and or C3 in
epidermal basement membrane), and indirect IF microscopy (autoantibodies
binding to the epidermal side of 1 M NaCl separated normal human skin
at titers of ù1:20) (Gammon et al, 1984). In addition, by immunoblotting
with keratinocyte extracts (Bernard et al, 1989), 22 BP sera had antibodies
against BP180 (including four BP sera with antibodies against both BP180
and BP230), and 11 BP sera had antibodies uniquely against BP230 (sera
uniformly diluted at 1:20). All PG patients were positive for anti-epidermal
basement membrane zone antibodies by a complement fixation assay
(Beutner et al, 1979), but bound neither BP180 nor BP230 in keratinocyte
extracts by conventional immunoblotting. Serum samples from EBA
patients immunoblotted type VII collagen in dermal extracts. All PV/PF
patients showed typical histopathology, direct and indirect IF microscopy
findings (autoantibodies reacting with the surface of epithelial cells of
monkey esophagus).
Cells and antibodies The African monkey kidney cell line COS-7,
which does not express endogenous BP180 and BP230 (Borradori et al,
1997; Niessen et al, 1997), was cultured in Dulbecco’s modified Eagle’s
medium (Gibco-BRL, Paisley, U.K.) supplemented with 10% (vol/vol)
bovine fetal calf serum, 100 U penicillin per ml, and 100 U streptomycin
per ml. The cells were grown at 37°C in a humidified, 5% CO2 atmosphere.
The following antibodies were used: mouse IgG1 monoclonal antibody
(MoAb) anti-FLAG M2 against the FLAG peptide (DYKDDDDK) (IBI,
Eastman Kodak, New Haven, CT); MoAb MYC 1–9E10.2 against a
defined c-myc epitope (Evan et al, 1985); mouse IgG1 MoAb 1 A8c and
the MoAb 233 directed against the ICD and ECD of BP180 (kindly
donated by Dr. K. Owaribe, Nagoya University, Nagoya, Japan) (Nishizawa
et al, 1993). Species-specific, affinity-isolated fluoroscein isothiocyanate-
conjugated goat anti-mouse IgG (Nordic Immunochemicals Laboratory,
Tilburg, The Netherlands), Texas red-conjugated goat anti-mouse IgG
(Amersham, Bucks, U.K.), and fluoroscein isothiocyanate-conjugated goat
anti-human IgG (Sigma, St. Louis, MO) were purchased.
cDNA constructs The BP180 nucleotide and protein sequences are
numbered according to Giudice et al (1992) and Hopkinson et al (1995),
respectively. Full-length BP180 was obtained from human keratinocyte
RNA by reverse transcriptase-polymerase chain reaction with primers
based on the published sequence of human BP180 (GenBank accession
number M91669) as reported elsewhere (Borradori et al, 1997). The
chimeric cDNA-constructs encoding the membrane localization sequence
of K-Ras (KMSKDGKKKKKKSKTKCVIM) (GenBank accession number
M54968 and M38506) fused with cDNA encoding either the entire ICD
of BP180 or the ICD with increasing internal truncations have been
previously described (Borradori et al, 1997). The various constructs were
cloned using the Xba I and/or a Not I restriction site in the eukaryotic
expression vector pCI-neo (Promega, Madison, WI). The clone coding
the entire ECD of BP180 including the last COOH-terminal 4 amino
acids (IALA) of the transmembrane domain, was derived from a novel
cDNA-construct BV13 kindly provided by Dr. K. Yancey (National Cancer
Institute, Bethesda, MD) (Haase et al, 1998). This cDNA BV13, the
correctness of which was verified by sequence analysis, was first cleaved
with XbaI and Not I. The Xba I and Not I blunt-ended fragment
from this clone was then implanted in frame into the blunt-ended Not I
site of the eukaryotic expression vector pcDNA3 (Invitrogen, San Diego,
CA), which at the 59 end of its multiple cloning site contained a
sequence encoding the myc-epitope (MEQKLISQQDL) (kindly provided
by Dr. E. Sander, The Netherlands Cancer Institute, Amsterdam). To
generate a cDNA clone coding for the ECD of BP180 lacking the NC16A
region, wild-type BP180 was used as a template in polymerase chain
reactions with recombinant Pfu-polymerase (Stratagene, La Jolla, CA) using
a 59 primer that contained a Not I site (underlined) and the nucleotides
corresponding to the sequence 1777 and 1800 of BP180 (italic) (CT-
CTCGCGGCCGCTATGGAACAGGAAAATGGAAATCTC), whereas
the 39 end primer contained a Not I and a Xba I site, as well as nucleo-
tides corresponding to the sequence 4579–4599 of BP180 (CGAT-
GCGGCCGCTCTAGATCACGGCTTGACAGCAATACT). The Not
1 cleaved polymerase chain reaction product was cloned into the Not I
digested pcDNA3 vector encoding the myc-epitope.
Transfection experiments COS-7 cells were transfected using the
DEAE-dextran method (Cullen, 1987) and assayed for gene expression
after 48 h.
Immunofluorescence microscopy Cells grown on glass coverslips in
6 well tissue culture plates were fixed with 1% formaldehyde in phosphate-
buffered saline (PBS) for 10 min and permeabilized with 0.5% Triton X-
100 for 5 min. After rinsing with PBS and blocking with 2% (wt/vol)
bovine serum albumin in PBS for 30 min at 37°C, the cells were incubated
with primary antibody for 30 min at 37°C, then washed three times with
PBS. Sera from BP patients and controls were uniformly diluted at 1:20
in PBS. The cells were then incubated with fluoroscein isothiocyanate- or
Texas-Red conjugated anti-mouse IgG or anti-human IgG for 30 min at
37°C. The coverslips were subsequently washed, mounted with Vectashield
(Vector, Burlinghame, CA), and viewed under a confocal laser scanning
microscope (LSM-410, Carl Zeiss AG, Zu¨rich, Switzerland).
Western blot analysis Cells were lyzed with 1% sodium dodecyl sulfate
in 25 mM Tris-HCl, pH 7.5, 4 mM ethylenediamine tetraacetic acid,
100 mM NaCl, 1 mM phenylmethylsulfonyl fluoride, 10 µg leupeptin
per ml, and 10 µg soybean trypsin inhibitor per ml. Protein concentration
in the cell lysates was determined with the BCA protein assay reagent
(Pierce, Rockford, IL). Equal amounts of protein were loaded on a
7.5% or 12% sodium dodecyl sulfate-polyacrylamide gel, separated, and
electrophoretically transferred to nitrocellulose sheets as previously described
(Niessen et al, 1997; Borradori et al, 1998). The filters were incubated in
TBST (10 mM Tris-HCl, pH 7.6, and 150 mM NaCl, 0.1% Tween-20)
containing 2% (wt/vol) bovine serum albumin and 2% (wt/vol) milk
powder for 12 h at 4°C. The nitrocellulose paper was then cut into strips
and incubated with a 1:20 dilution of each tested serum in TBS-0.5%
Nonidet P40 for 2 h at room temperature. After washing four times for
5 min in TBS-0.5% Nonidet P40, the strips were then incubated with
peroxidase-conjugated goat anti-human IgG (H 1 L) antibody (Institut
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Figure 1. Schematic representation of wild-type and mutant forms
of BP180. The upper two cDNA constructs encode either the extracellular
domain of BP180 (clone A) or the ECD lacking the NC16A region (clone
B). The lower four cDNA constructs (clones C–F) represent chimeric
cDNA constructs encoding the membrane localization sequence of K-Ras
fused to the intracellular domain (ICD) of BP180 with increasing internal
truncations. ICD, intracellular domain; ECD, extracellular domain; M,
c-myc tag; F, FLAG tag; DSR, degenerate set of four 24–26 residue tandem
repeats; CX, membrane localization sequences of K-Ras. Truncations
introduced by cloning procedures are indicated by the segment of amino
acids that were deleted. The protein sequence of BP180 is numbered
according to Hopkinson et al (1995).
Pasteur, Marnes la Coquette, France) or goat anti-mouse Ig (Amersham
Life Sciences, Zu¨rich, Switzerland). After washing, the strips were developed
with 3,39-diaminobenzidine-4 HCl (0.5 mg per ml) in 100 mM Tris-HCl
pH 7.4 containing 0.01% H2O2.
Affinity purification studies IgG from a representative BP patient was
affinity purified against the ECD of BP180 immobilized on a nitrocellulose
paper. Extracts of transfected COS-7 cells were resolved by electrophoresis
and transferred to nitrocellulose paper as described above. Horizontal strips
of nitrocellulose paper containing the ECD of BP180 (or control peptides)
were incubated with patient serum (diluted 1:5) overnight at 4°C. Bound
antibodies were eluted from experimental (and control) nitrocellulose strips
with 100 mM glycine, pH 2.5, for 10 min, then immediately neutralized
with one-tenth volume of 1 M Tris, pH 8.0, and finally tested against the
ICD and the ECD (control) of BP180 by immunoblotting analyses as
described above.
RESULTS
Circulating IgG from BP patients bind multiple epitopes of
the ECD of BP180 Most sera from BP patients contain IgG
that bind the NC16A region of the ECD of BP180 (Giudice et al,
1993; Liu et al, 1993; Zillikens et al, 1997a). To further characterize
the antigenic sites recognized on BP180, we assayed by immuno-
blotting the reactivity of BP sera against a series of mutant forms
of BP180, which were expressed in COS-7 cells after transfection
with the corresponding cDNA (Fig 1). To identify the recombinant
proteins, the constructs were tagged at their 59 end with either the
myc-epitope or the FLAG peptide. Twenty-two of 22 (100%) BP
sera that immunoblotted BP180 in keratinocyte extracts, reacted
against a BP180 mutant encompassing the entire ECD of BP180
(clone A). (Fig 2, Table I). The bound protein had an apparent
molecular weight of 100 kDa, as predicted on the basis of the
corresponding cDNA sequence, and was recognized by both the
MoAb 9E10 anti-myc-epitope and the MoAb 233 against the ECD
of BP180 (not shown). Only three of these 22 (14%) BP sera
contained IgG that recognized clone B-encoded BP180 recombin-
ant consisting of the ECD of BP180 devoided of the NC16A
region (Fig 2). The bound protein was close to its predicted
molecular weight of 93 kDa. In addition, one of 11 BP patients
(9%) exhibiting exclusively BP230-reactivity with keratinocyte
extracts recognized clone A-encoded protein (not shown). In
Figure 2. IgG autoantibodies from BP patients bind multiple
antigenic regions on BP180. Reactivity of BP sera was assessed by
immunoblotting as described in Materials and Methods against BP180 mutants
(listed in Fig 1), which were expressed in transfected COS-7 cells.
Reactivity against (a) clone A-, (b) clone B-, (c) clone C-, (d) clone D-,
(e) clone E-, (f) clone F-encoded BP180 mutants. Lanes 1–8 correspond
to sera from patients BP2, BP6, BP8, BP12, BP16, BP21, a normal human
volunteer, MoAb 9E10 anti-myc-epitope (A and B) or MoAb anti-FLAG
peptide (c, d), respectively. Proteins closed to their predicted mass of 101,
93, 51.7, 35.3, 30.9, 21.4 kDa for clones A, B, C, D, E, and F, respectively,
are recognized (arrow) by MoAb 9E10 (a, b) or MoAb anti-FLAG peptide
(c–f). Clone C-encoded mutant appeared as a doublet (c), most likely due
to proteolytic degradation. Each of the six BP sera exhibits a different
pattern of immunoreactivity and is representative of the reactivity patterns
observed with other BP sera. Note that some additional reactive bands
were occasionally found with both experimental and control sera and most
likely represented either unspecific background or reactivity against proteins
of unknown identity in COS-7 cell extracts. Samples were separated by
7.5% (a, b) or 12.5% (in c–f) sodium dodecyl sulfate-polyacrylamide gel
electrophoresis under nonreducing conditions.
contrast, serum samples from normal volunteers (n 5 8), patients
with EBA (n 5 2), and patients with PV/PF (n 5 8) did not
recognize clone A- or clone B-encoded recombinant proteins
(not shown). The results indicate that, although BP180-specific
autoantibodies predominantly recognize epitopes of the NC16A
region, additional epitopes of the ECD of BP180 exist.
IgG antibodies from BP patients immunoblot a recombinant
protein encompassing the ICD of BP180 Prompted by the
observation that a cDNA clone coding for a portion of the
cytoplasmic domain of BP180 was isolated using a BP serum sample
(Hopkinson et al, 1992), we examined the reactivity of BP sera
using extracts of COS-7 cells transfected with a cDNA construct
coding for a chimeric protein consisting of the ICD of BP180
fused to the membrane localization sequence of K-Ras (clone C).
Thirteen of 22 (59%) BP patients with BP180-reactivity contained
IgG autoantibodies that reacted with clone C-encoded BP180
mutant, a protein of µ52 kDa (Fig 2, Table I). The electrophoretic
mobility of this protein was the same as that of the protein
recognized by the MoAb against the FLAG peptide and the MoAb
1A8c against the ICD of BP180 (not shown). When BP sera
showing uniquely BP230-reactivity were tested, two of 11 (18%)
sera immunoblotted clone C-encoded protein. In contrast, serum
samples from normal volunteers (n 5 8), patients with EBA (n 5
2), and patients with PV/PV (n 5 8) were negative. Finally, to
exclude the possibility that autoantibodies directed against the ECD
of BP180 cross-reacted with its ICD, IgG from a representative
BP patient (BP7) with circulating autoantibodies binding both the
ECD and the ICD of BP180 was affinity-purified against the ECD
of BP180 and tested against the ICD by immunoblotting. Patient’s
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Table I. Clinical status of bullous pemphigoid (BP) patients and reactivity of their sera in immunoblot analyses against
clone A-, clone B-, or clone C-encoded BP180 mutants and in immunofluorescence microscopy studies of COS-7 cells
expressing clone C-encoded protein. All patients sera immunoblotted BP180 in keratinocyte extracts
Immunoblottingb Immunofluorescenceb
Patients Age Duration Skin lesions Treatmenta A B C C
BP1 77 10 y back, limbs CB 4 mg, PDN 30 mg 11 – – –
BP2 81 1 mo generalized Aza 100 mg, Pred 60 mg 1 – 1 1
BP3 83 1 mo limbs none 1 1 11 1
BP4 92 1 mo back, mouth CB 4 mg, PDN 25 mg 11 – 11 1
BP5 75 2 mo trunk CB 4 mg, PDN 15 mg 1 – 1 1
BP6 76 6 mo generalized CB 6 mg, PDN 30 mg 11 – 11 –
BP7 74 2 mo limbs, face CTX 100 mg, PDN 20 mg 11 – 11 1
BP8 86 1 mo limbs, trunk CB 6 mg, PDN 40 mg 11 1 11 –
BP9 75 5 mo generalized CB 4 mg, PDN 40 mg 11 – 11 –
BP10 85 4 mo limbs, trunk CB 6 mg, PDN 40 mg 1 – – –
BP11 53 2 mo trunk PDN 40 mg 1 – 1 –
BP12 87 5 wk trunk Aza 100 mg, PDN 40 mg 11 – 11 1
BP13 70 4 y none none 11 – – –
BP14 98 2 wk limbs PDN 40 mg 11 – – –
BP15 61 6 y none none 1 – – –
BP16 55 8 wk trunk, arms Aza 50 mg, PDN 16 mg 11 – – –
BP17 92 2 wk trunk Aza 100 mg, PDN 40 mg 11 – 11 1
BP18 91 3 mo generalized Aza 100 mg, PDN 100 mg 11 – 11 1
BP19 96 1 mo trunk none 11 – – 1
BP20 88 1 y generalized Aza 50 mg, PDN 30 mg 11 – – –
BP21 86 3 mo limbs, face Aza 150 mg, PDN 30 mg 11 1 11 –
BP22 90 1 mo limbs, trunk PDN 50 mg 11 – – –
Positive sera 22/22 (100%) 3/22 (14%) 13/22 (59%) 9/22 (41%)
aCB, chlorambucil; CTX, cyclophosphamide; PDN, prednisone.
bIntensity of the labeling: 11, strong positive; 1, positive; –, negative.
Figure 3. Affinity-purified IgG antibodies against the ECD of BP180
do not bind its ICD when reblotted. IgG autoantibodies from a
representative BP patient (BP7) were affinity purified against the ECD of
BP180 (or 200 kDa control polypeptides) immobilized on nitrocellulose
paper and assessed against the ICD of BP180 (and its ECD, control) by
immunoblotting as described in Materials and Methods. Reactivity against
clone A- (lanes 1–4) and clone C- (lanes 5–8) encoded mutants
corresponding to the ECD and ICD of BP180, respectively. Lane 1, MoAb
9E10 anti-myc-epitope; lanes 2 and 6, BP7 serum; lanes 3 and 7, BP7
serum affinity-purified IgG against the ECD of BP180; lanes 4 and 8,
affinity-purified IgG against 200 kDa control peptides; lane 5, MoAb anti-
FLAG peptide. The migration position of the two BP180 mutants is
indicated (arrow). Samples were separated by 7.5% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis under nonreducing conditions.
IgG affinity purified against the ECD of BP180 did not immunoblot
the ICD (Fig 3), but was reactive against the ECD in the same
manner as total serum IgG from this patient. In contrast, eluates
from control proteins showed no reactivity with either the ECD
or the ICD of BP180. The results indicate that the ICD of BP180
harbors antigenic sites that are specifically recognized by IgG
autoantibodies from BP patients.
IgG autoantibodies from BP patients stain transfected COS-
7 cells expressing the ICD of BP180 To further ascertain that
patients’ sera bind the ICD of BP180, confocal laser IF microscopy
studies of transfected COS-7 cells expressing the ICD of 180 were
performed. As previously described (Borradori et al, 1997), the
mutant protein encoded by clone C was properly expressed at the
plasma membrane in transfected cells as assessed using the MoAb
Figure 4. Sera from BP patients stain transfected COS-7 cells
expressing the ICD of BP180. Confocal double immunofluorescence
microscopy. Cells grown on glass coverslips were transfected with clone
C encoding a chimeric protein composed of the ICD of BP180 combined
with the membrane targeting sequence of K-Ras. After 36 h, cells were
fixed with 1% formaldehyde, permeabilized with 0.5% Triton X-100, and
subjected to double immunofluorescence using the MoAb anti-FLAG M2
peptide (A, C) and a serum from a normal volunteer (B), or BP12 serum
(D). Species-specific, Texas red-conjugated goat anti-mouse IgG (A, C)
and fluoroscein isothiocyanate-conjugated goat anti-human IgG (B, D).
Scale bar : 25 µm.
against the FLAG peptide tag (Fig 4). When cells were simultan-
eously processed with BP sera, nine of 22 (41%) BP sera with
BP180-reactivity using keratinocyte extracts stained the transfected
cells in a pattern indistinguishable from that obtained with the
MoAb against the FLAG peptide (Fig 4, Table I); however, only
eight of the 13 (62%) BP sera that immunoblotted clone C-
encoded protein were positive in IF analysis, whereas the remaining
five immunoblot-positive BP sera (38%) did not show any obvious
staining of transfected cells. Only one of nine (11%) IF-positive
BP sera was negative on immunoblot analysis. Finally, serum
samples from BP patients with BP230 reactivity (n 5 11), EBA
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Table II. Reactivity in immunoblot analyses of BP sera
against clone D-, clone E-, or clone F-encoded BP180
mutants. These patients sera contained IgG
immunoblotting clone C encoded BP180 recombinant
BP sera D E F
BP2 –a – –
BP3 1 1 –
BP4 1 1 –
BP5 1 1 –
BP6 1 1 –
BP7 1 1 –
BP8 – – –
BP9 – – –
BP11 1 1 –
BP12 11 11 11
BP17 11 1 –
BP18 1 1 1
BP21 1 – –
Positive sera 10/13 (77%) 9/13 (69%) 2/13 (15%)
aInterpretation of the results: 11, strong positive; 1, positive; –, negative.
(n 5 2), PV/PV (n 5 8), and normal volunteers (n 5 8) did not
react with clone C-encoded protein in these IF microscopy studies.
These results confirm that the ICD of BP180 contains additional
antigenic sites and further suggest that immunoblot analysis is more
sensitive than IF microscopy studies in detecting antibodies to the
ICD of BP180.
The central region of the ICD of BP180 contains immuno-
dominant epitopes To map the antigenic sites recognized
by BP autoantibodies in the ICD of BP180, 13 BP sera that
immunoblotted the ICD of BP180 were assayed against a series of
mutant proteins, which consisted of the membrane localization
sequence of K-Ras fused to the ICD of BP180 with increasing
internal deletions (clones D, E, and F) (Fig 2, Table II). Ten of
these 13 (77%) BP sera were reactive against clone D-encoded
BP180 mutant showing a deletion of a 159-amino acids stretch in
the central portion of the ICD of BP180. In addition, nine of the
13 (69%) BP sera also reacted with clone E-encoded protein with
a deletion of a 202-amino acids stretch. In contrast, the protein
encoded by clone F, which exhibited an additional deletion of 87
amino acids towards the NH2-terminus, was recognized by only
two of the 13 (15%) BP sera. The results indicate that BP sera
recognize multiple epitopes located in the ICD of BP180. The
observation that the mutant BP180 protein consisting of a 265-
amino acids segment (clone E) was still recognized by the majority
of these BP sera, whereas a BP180 mutant with an additional 87-
amino acids deletion towards the NH2-terminus was not (clone
F), suggested that major antigenic determinants reside within this
87-amino acids stretch. It is noteworthy that this region contains
two stretches of seven amino acids (residues 130–136 and 175–
181) showing high antigenicity as predicted by the James and Wolf
algorithm (Jameson and Wolf, 1988). In addition, MoAb 1A8c
against the ICD of BP180 is reactive against this 87-amino acids
segment (Borradori et al, 1997), suggesting that this region is also
immunogenic in mice.
IgG antibodies from PG patients bind the NC16A region of
BP180 Previous studies have suggested that sera from PG patients
recognize the NC16A region of the ECD of BP180 (Giudice et al,
1993). To further assess the reactivity of PG sera, six PG sera were
tested using clone A-, clone B-, and clone C-encoded proteins.
Five of six (83%) PG sera immunoblotted the ECD of BP180
(clone A) (Fig 5), whereas none (0%) of the sera recognized a
recombinant consisting of the ECD of BP180 devoid of the NC16A
region (clone B). Finally, no reactivity was observed against the
ICD of BP180 (clone C) in both immunoblotting (Fig 5) and IF
microscopy studies of transfected COS-7 cells (not shown). Thus,
the immune response to BP180 in PG patients appears to be largely
restricted to the NC16A region.
Figure 5. IgG autoantibodies from PG patients bind the ECD of
BP180. Reactivity of PG sera was assessed by immunoblotting as described
in Materials and Methods against clone A- and clone C-encoded mutant
forms of BP180 (a and b, respectively). Lanes 1–8 correspond to sera from
patients PG1, PG2, PG3, PG4, PG5, PG6, a normal human volunteer,
MoAb 9E10 anti-myc epitope (in a) or MoAb anti-FLAG peptide (b),
respectively. The migration position of the two BP180 mutants is indicated
by an arrow. Samples were separated by 7.5% (a) or 12.5% (b) sodium dodecyl
sulfate-polyacrylamide gel electrophoresis under nonreducing conditions.
DISCUSSION
This study demonstrates that BP autoantibodies recognize antigenic
sites spread over the entire BP180 molecule. BP sera were found
to contain IgG autoantibodies that predominantly recognize not
only the NC16A region on the ECD of BP180, but also the central
portion of its ICD.
Previous studies using bacterial fusion proteins have indicated
that the reactivity to BP180 in BP patients is largely restricted to
the NC16A region, a 76-amino acid stretch located between the
transmembrane domain and the large extracellular collagenous
portion of BP180 (Giudice et al, 1993, 1994; Matsumura et al,
1996; Zillikens et al, 1997b). Our study confirms that BP180-
reactive autoantibodies recognize the NC16A region; however,
the observation that at least 13% of the BP180-reactive sera have
antibodies against a BP180 mutant encompassing the ECD without
the NC16A region (clone B) indicates that epitopes other than the
NC16A region exist on the ECD of BP180. Support for this idea
derives from recent findings demonstrating that some BP sera bind
the distal COOH-terminal region of BP180 (Balding et al, 1996).
These results provide an explanation for the observation that
preadsorption of BP sera with the NC16A region does not always
completely abolish their reactivity against the ECD of BP180
(Zillikens et al, 1997b).
The novel finding of our study is that a substantial number of
BP180-reactive sera contain IgG autoantibodies that bind the ICD
of BP180. Immunoblot analysis demonstrated that 59% of BP180-
reactive sera contained IgG that recognized a mutant protein
encompassing the ICD of BP180. In addition, IF microscopy
studies disclosed that 41% of BP180-reactive sera stained COS-7
cells expressing the ICD of BP180. Finally, affinity purification
studies using circulating IgG autoantibodies of a representative BP
patient indicated that there was no antigenic cross-reactivity
between the ECD and the ICD of BP180. These results firmly
establish that anti-BP180 reactivity is not confined to the ECD of
BP180, but that additional antigenic sites exist on the ICD.
Specifically, by using a series of mutants with increasing internal
deletions of the ICD of BP180, many BP sera were found to
recognize a segment of 87 amino acids towards the NH2-terminus
of BP180. This segment, which is also targeted by MoAb 1A8c
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against BP180 (Borradori et al, 1997), thus appears to encompass a
major antigenic determinant.
The failure to characterize the antigenicity of the ICD of BP180
in previous studies may be explained by the fact that the reactivity
of BP sera was exclusively assessed utilizing bacterial fusion proteins
encompassing either the NC16A region or the distal COOH-
terminus of the ECD of BP180, whereas the ICD was not tested.
Furthermore, the use of recombinant BP180 forms expressed in an
eukaryotic system, which yields proteins with potential proper
post-translational modifications, might have facilitated the identi-
fication of additional autoantibody specificities in this study.
The identification of at least two regions of autoantibody-
reactivity on BP180 is not surprising. Ample evidence exists
indicating that during the course of an autoimmune disease B and
T cell responses are not restricted to a unique ‘‘immunodominant’’
epitope, but that additional ‘‘secondary’’ epitopes within the same
proteins are recognized (Vanderlugt and Miller, 1996; Chan et al,
1998). This phenomenom termed ‘‘epitope spreading’’ appears to
be important for the perpetuation and progression of the disease.
The observation that in BP two distinct molecules (i.e., BP180
and BP230) are targeted on which multiples epitopes are recognized
(Rico et al, 1990; Tanaka et al, 1991; Giudice et al, 1993; Balding
et al, 1996; Zillikens et al, 1997b), suggests that epitope spreading
also occurs in this disorder; however, although it has been conjec-
tured that autoantibodies to the ECD of BP180 have an initiatory
role in the development of BP, whereas antibodies directed against
cytoplasmic antigenic determinants such as BP230 arise as a second-
ary event (Giudice et al, 1993; Liu et al, 1993), experimental data
supporting this hypothesis are missing. Although in this study no
obvious correlation could be established between clinical stage or
extent of the disease and the fine specificities of anti-BP180
autoantibodes, prospective studies aimed at characterizing the
epitopes on BP180 and BP230, which are recognized by B cells,
are required to verify this hypothesis. In addition, there is evidence
that autoreactive T cell responses to BP180 are important in
inducing B cells reactivity to BP180 (Bu¨dinger et al, 1998). The
nature of the antigenic determinants recognized by T cells, which
provide help to B cells to produce autoantibodies, is likely to be
critical for the initiation of the events leading to overt pathology.
Because recent studies have shown that autoantibodies can
penetrate into living cells, reach their intracellular targets, and affect
their function (Alarco´n-Segovia et al, 1996), it is conceivable
that autoantibodies against the ICD of BP180 have pathogenic
significance. Thus, it is tempting to correlate our epitope mapping
results with the finding that the ICD of BP180 is functionally
important. First, it has been shown that the ICD of BP180 contains
sequences critical for the incorporation of the protein into HD
(Hopkinson et al, 1995; Borradori et al, 1997). Specifically, the 87-
amino acid segment recognized by many sera reactive against the
ICD is required for the recruitment of the protein into HD
(Borradori et al, 1997). Second, the central region of the ICD of
BP180 harbors binding site(s) critical for the efficient interaction
of BP180 with the β4 subunit of the α6β4 integrin (Borradori
et al, 1997; Aho and Uitto, 1998; Schaapveld et al, 1998). Based
on these findings, it is possible that autoantibodies to the ICD of
BP180 contribute to dermo–epidermal separation by impairing the
interaction of BP180 with other elements of HD and thus their
stabilization.
This report strengthens the idea that PG sera predominantly
recognize epitopes localized within the NC16A region (Giudice
et al, 1993, 1994), as five of six (83%) PG sera bound exclusively
this region. In apparent contrast to what has been found with BP
sera, none of the PG sera showed reactivity against the ICD of
BP180; however, because of the small number of PG sera analyzed,
further studies are needed to assess whether this lack of reactivity
against the ICD is a distinctive feature of PG, which may explain
differences in certain clinical and immunopathologic features
observed between BP and PG.
Finally, immunoblot analyses using mutant forms of BP180
expressed in transfected COS-7 cells appear to represent a rapid,
efficient, and specific technique to detect circulating autoantibodies
against BP180. In all patients showing reactivity against BP180 by
conventional immunoblotting using keratinocyte extracts, anti-
BP180 autoantibodies were detected by this approach. In addition,
the method appeared to increase the sensitivity of the assay for the
detection of anti-BP180 antibodies, because three of 11 (27%) BP
sera and five of six (83%) PG sera, which were otherwise BP180-
negative by immunoblotting studies, showed reactivity against
either the ECD or the ICD of BP180.
In conclusion, our study demonstrates that multiple antigenic
sites are recognized on BP180. Two major immunodominant
regions exist, which are localized to the extracellular, membrane-
proximal NC16A region and to the central portion of the ICD of
BP180. It is likely that this heterogeneous immune response to
BP180 reflects intramolecular epitope spreading and may have
pathogenic significance.
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